Insulet (PODD) Projected to Post Quarterly Earnings on Wednesday

Insulet (NASDAQ:PODD) will likely be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Insulet to announce earnings of $1.45 per share and revenue of $787.3890 million for the quarter. Insulet has set its FY 2026 guidance at 6.210- EPS. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the prior year, the firm earned $1.02 earnings per share. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. On average, analysts expect Insulet to post $6 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Insulet Stock Performance

NASDAQ PODD opened at $169.70 on Tuesday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet has a 52-week low of $138.79 and a 52-week high of $354.88. The business’s 50-day moving average price is $155.56 and its 200 day moving average price is $196.91. The firm has a market cap of $11.75 billion, a P/E ratio of 39.47, a P/E/G ratio of 1.15 and a beta of 1.10.

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Insulet

Several institutional investors have recently modified their holdings of PODD. University of Texas Texas AM Investment Management Co. purchased a new position in Insulet in the 4th quarter valued at approximately $26,000. DV Equities LLC purchased a new stake in Insulet during the fourth quarter worth $28,000. Mcguire Capital Advisors Inc. purchased a new stake in Insulet during the fourth quarter worth $29,000. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its holdings in Insulet by 68.8% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 135 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 55 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC acquired a new stake in Insulet in the third quarter valued at $49,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet insiders have reportedly made four open-market purchases totaling roughly $2.4 million over the past six months, including purchases by CEO Ashley McEvoy. Insider buying may signal management’s confidence after the stock’s substantial decline. Quiver Quantitative Insulet analysis
• Positive Sentiment: The company’s latest reported quarter showed strong momentum: revenue rose approximately 34% year over year to $761.7 million, while earnings exceeded analyst expectations. The Omnipod 5 system also continues to support Insulet’s long-term growth narrative. Quiver Quantitative Insulet analysis
• Neutral Sentiment: Analysts cited in the coverage remain generally constructive, with recent buy-equivalent ratings and a median price target of $220, though several individual targets have been reduced to the $172-$190 range. This reflects potential upside but also uncertainty surrounding the company’s recovery.
• Negative Sentiment: Several law firms announced or promoted a securities class action against Insulet and certain executives. The complaints allege that the company made materially misleading statements about manufacturing controls, product safety and reliability, and the scope of Omnipod manufacturing defects following a recall. The allegations have not been proven. Bronstein Gewirtz Grossman lawsuit announcement Levi and Korsinsky lawsuit notice
• Negative Sentiment: Investors who purchased PODD shares during periods cited in the complaints—generally February 21 or May 21, 2025 through May 26, 2026—are being urged to seek lead-plaintiff status by August 31, 2026. The litigation creates potential financial, reputational and regulatory risks and may continue to weigh on valuation. Robbins LLP class action notice Faruqi and Faruqi shareholder notice

Analyst Ratings Changes

A number of analysts have weighed in on PODD shares. Stifel Nicolaus decreased their price objective on Insulet from $250.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Sanford C. Bernstein cut their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Oppenheimer decreased their price target on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $233.38.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.